Filamentous Fungi Stress Tolerance Patents: Leaders & Trends 2026
- Concentrated at the top. The five leading assignees hold 236 of 717 records in scope (32.9%), with a long tail of single- and few-filing entrants behind them.
- Filing has cooled from its 2019 peak. Activity ran from 25 records in 2017 to a peak of 47 in 2019, then fell from 34 in 2021 to 9 in 2024 — a -74% move over that three-year span, before the reporting lag thins out 2025-2026.
- Genetic engineering claims dominate. 96.8% of the 717 records sit in C12N (microorganisms & genetic engineering), while measurement (C12Q, 39.7%) and peptide/protein claims (C07K, 34.6%) trail well behind.
Filing growth compares 2021 (34 records) with 2024 (9) — a three-year span. 2024 is the most recent year we treat as complete: publication lags filing by roughly 18 months, so 2025 onwards are still filling in and any growth rate that ends there would understate the field. Top-5 share is the combined record count of the five largest assignees divided by all 717 records in scope (CR5), not by the ranked leaders only.
What this landscape covers
This dataset tracks patent families combining filamentous fungus or recombinant fungus host-cell claims with a documented stress-tolerance phenotype — solvent, acid, osmotic, oxidative, heat shock or membrane stability — filed under the core genetic-engineering and enzyme-testing classifications (C12N15/80, C12N1/14, C12Q1/68). It spans publications from 2015 through the 2026-07-31 cut-off, covering 717 records in total.
The scope favours engineered production strains — industrial enzyme hosts, fermentation platforms and screening methods — over purely academic strain descriptions, because the search terms require an explicit stress-tolerance claim alongside the fungal host-cell language. Readers should treat family counts, not raw document counts, as the more reliable measure of underlying invention density.
Filing trends and technology composition
Two views of the same 717-record set: how filing volume has moved year over year, and which IPC subclasses carry the claim density.
A 2019 peak, then a documented pullback
Filings rose from 25 records in 2017 to a peak of 47 in 2019. From 2021's 34 records to 2024's 9, the recorded drop is -74% — the last year that can be read as a complete filing year, since publication lags filing by roughly 18 months and 2025-2026 will still fill in.
Genetic engineering carries the claim load
C12N (microorganisms & genetic engineering) appears in 96.8% of the 717 records, effectively a gating classification for this search. C12Q (enzyme/DNA testing, 39.7%) and C07K (peptides & proteins, 34.6%) are the next-heaviest classes, with fermentation synthesis (C12P, 32.2%) and food applications (A23L, 15.3%) forming a smaller secondary tier. Because records can carry several IPC codes, these shares are read against the 717-record total, not against each other.
Shares are the percentage of the 717 records in scope. A patent can carry several IPC classes, so the shares add up to more than 100%.
Go deeper on Filamentous Fungi Stress Tolerance with Eureka
This page is one run against one query. Ask Eureka your own question about filamentous fungi stress tolerance and every answer comes back with the patent numbers behind it.
Try EurekaRepresentative filing and most-cited prior art
Manipulation of genes involved in signal transduction to control fungal morphology during fermentation and production
The present disclosure provides a microbial genomic engineering method and system for transforming, screening, and selecting filamentous fungal cells that have altered morphology and/or growth under specific growth conditions. The method and system utilize high-throughput (HTP) methods to produce filamentous fungal production strains with a desired morphological phenotype.Filed by Zymergen Inc., published 2019-12-12 as US20190376070A1.
| # | Publication no. | Patent title | Citations |
|---|---|---|---|
| 1 | US20150082478A1 | Plant genome modification using guide RNA/CAS endonuclease systems and methods of use | 433 |
| 2 | US5783431A | Methods for generating and screening novel metabolic pathways | 429 |
| 3 | US5824485A | Methods for generating and screening novel metabolic pathways | 346 |
| 4 | WO1996034112A1 | Methods for generating and screening novel metabolic pathways | 180 |
| 5 | US9988624B2 | Microbial strain improvement by a HTP genomic engineering platform | 170 |
| 6 | US20170159045A1 | Microbial strain improvement by a HTP genomic engineering platform | 150 |
| 7 | US5302527A | Nitrate reductase as marker for filamentous fungi | 143 |
| 8 | WO2002045524A2 | Prolyl endoprotease from aspergillus niger | 138 |
| 9 | WO2001038503A2 | Novel human protein kinases and protein kinase-like enzymes | 121 |
| 10 | US20100086978A1 | Increased isoprene production using the archaeal lower mevalonate pathway | 112 |
Citation counts accumulate over time and favour older filings; read them as a signal of influence within this corpus, not as a ranking of current technical importance.
Each row carries its publication number; clicking a row searches Eureka by that number.
Put your own technology through the same analysis
Eureka on the web
When you want the answer in the next five minutes.
The agent works the prompt against patents and technical literature, citing every source.
Run your analysis now →MCP server & REST API
When it has to run inside your own pipeline.
Patent search, landscape analysis and assignee resolution as MCP tools. Drop them into any agent framework, or call REST directly.
Browse MCP servers →What the numbers say
Three findings that shape how a freedom-to-operate or licensing search should be scoped in this space.
A short leader group, then a long tail
The five leading assignees hold 236 of the 717 records in scope. The tenth-ranked assignee holds only 14, and the ranking runs to 100 companies with most holding a handful of families each — a classic head-and-tail structure rather than a duopoly.
Filing has pulled back from its 2019 peak
After peaking at 47 records in 2019, filing volume declined through the early 2020s; the 2021-to-2024 window shows a -74% drop to 9 records. 2025-2026 figures will rise as the publication lag closes, so this should be read as the most recent complete trend, not a final word on the field's direction.
Genetic-engineering claims are the gate
Almost every record in scope carries a C12N code, confirming that host-cell engineering is the near-universal chassis for stress-tolerance claims here. The more differentiated claim space sits in the secondary classes — C12Q testing methods, C07K peptide constructs, and A23L food-application claims — where filing density is lower.
Foundational prior art is old and still cited
The most-cited records in this set date to the mid-1990s through 2015 and centre on genome modification and metabolic-pathway screening platforms. Their citation counts are large because they have had years to accumulate references, not because they are the newest technical statement of the art.
Eureka can read the same corpus for gaps instead of for coverage: under-claimed branches adjacent to filamentous fungi stress tolerance, with the prior art for and against each one.
Who holds the ground, and what is still open
The leader group is built on industrial enzyme and fermentation platforms; the recent-year momentum data shows most of the named leaders with no new records in the latest year, consistent with the broader filing pullback.
A single assignee well ahead of the field
The leading assignee's 82 records sit well above the fifth-place holder's 36, indicating a genuinely dominant filer rather than a tightly bunched top group. Recent-year momentum data shows this activity has not continued into the latest tracked year for most of the named leaders.
Co-assignee activity is limited and inventor-centred
Only 10 co-assignee pairs appear in this dataset, and the strongest links are between named individual inventors rather than company-to-company joint filings. This suggests most patenting here happens inside single organisations rather than through formal filing partnerships.
US-first filing, with strong EPO and PCT follow-through
The United States receives the largest single share of filings (215), ahead of the EPO (134) and WIPO/PCT (105). Australia, Canada and Germany each carry meaningfully smaller counts, pointing to a filing strategy anchored in the US with selective international extension rather than broad global filing as standard practice.
| Assignee | Recent year | YoY |
|---|---|---|
| Pioneer Hi-Bred International, Inc. | 1 | — |
| Danisco US Inc. | 0 | — |
| Zymergen Inc. | 0 | — |
| DSM IP Assets B.V. | 0 | — |
| Novozymes A/S | 0 | — |
| Sugen, Inc. | 0 | — |
| BASF Enzymes LLC | 0 | — |
| Marlow Foods Limited | 0 | — |
Where to take this next
The landscape points to specific next steps depending on whether the goal is freedom-to-operate, licensing, or new filing strategy.
Scope a freedom-to-operate search
With 32.9% of records held by five assignees, a targeted FTO review of the leader group's claims is more efficient than a blanket search across all 717 records.
Explore Eureka for FTO scopingTrack the leader's continuation activity
The top assignee's 82-record position warrants a continuation and family-status check before committing to a design-around strategy in its core claim areas.
Monitor assignee activity in EurekaTest claims in under-filed branches
Lower-density branches such as osmotic-stress assays and food-grade acid tolerance carry fewer blocking claims and may offer more room for a first-mover filing.
Draft claims with EurekaCommon questions on this landscape
The assignee ranking in this dataset covers 100 companies, with the leading assignee holding 82 of the 717 records in scope and the fifth-ranked holder at 36. The top five combined account for 236 records, or 32.9% of all records in scope, while the remaining ranked companies hold progressively smaller counts down to single-digit filings. This head-and-tail structure means a licensing or FTO review should prioritise the leader group first, then check the long tail for narrower, more specific claims that the leaders may not cover.
Filing peaked at 47 records in 2019 and has declined since; the 2021-to-2024 window shows a drop from 34 to 9 records, a -74% move. Because publication lags filing by roughly 18 months, the 2025 and 2026 figures in any chart will still be filling in and should not be read as confirming a continued decline. Treat 2024 as the most recent year with a reasonably complete count.
US20190376070A1, filed by Zymergen Inc. and published in December 2019, claims a high-throughput genomic engineering method and system for producing filamentous fungal strains with altered morphology or growth under specified conditions. It is a platform-level claim around screening and strain selection rather than a single stress-tolerance mechanism, which makes it relevant to anyone using HTP screening workflows on filamentous fungal hosts. Reviewing its specific claim language against your own screening pipeline is a reasonable first check before assuming freedom to operate in this area.
C12N (microorganisms and genetic engineering) appears in 96.8% of the 717 records in this dataset, making it close to a universal classification for this search. C12Q (enzyme and DNA testing methods) and C07K (peptides and proteins) follow at 39.7% and 34.6% respectively, with C12P (fermentation synthesis) and A23L (food applications) forming a smaller secondary tier. Because a single record can carry multiple IPC codes, these percentages should be read against the 717-record total rather than summed together.
Based on the technology composition in this dataset, lower-density branches such as osmotic-stress screening assays, food-grade acid-tolerant strain claims, and combined dual-tolerance constructs (heat shock plus oxidative stress) carry fewer records than the dominant genetic-engineering chassis claims. These branches are not proven to be open — that requires a dedicated FTO search — but their lower filing density relative to the core C12N claim space makes them a reasonable starting point for scoping new filings or licensing-in opportunities.
Research Filamentous Fungi Stress Tolerance in depth with Eureka
Go past this page: query the whole filamentous fungi stress tolerance corpus yourself, in your own scope.
Every answer comes back with patent numbers you can open.
Disclaimer. This page is generated from Patsnap Eureka data drawn from a limited snapshot of global patent and scientific-literature records, and is provided for general information and reference only.
Patent data carries inherent limitations: recent filings (typically the most recent 18–24 months) are under-counted due to standard publication lag; counts may be reported at either a patent-family or a patent-record basis and are not always directly comparable; classification, applicant-name, and citation data may contain errors, duplicates, or omissions; and the underlying search query defines and constrains the scope shown. As a result, the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing on this page constitutes an exhaustive prior-art, novelty, freedom-to-operate, or validity search, nor does it constitute legal, financial, investment, or professional advice, and it should not be relied upon as such. Any patent, commercial, or strategic decision should be verified independently and reviewed with qualified patent, legal, and domain professionals. Patsnap makes no warranties, express or implied, as to the accuracy, completeness, or fitness for any particular purpose of the information presented.
Machine translation. Assignee and organisation names originally recorded in Chinese, Japanese or Korean have been rendered into English by an AI translation step so that the tables stay readable. These renderings are best-effort and may not match a company’s registered English name; the original name is what the underlying patent record carries, and it is what any Eureka query launched from this page uses.